<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="296">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792138</url>
  </required_header>
  <id_info>
    <org_study_id>251440</org_study_id>
    <nct_id>NCT04792138</nct_id>
  </id_info>
  <brief_title>Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis.</brief_title>
  <acronym>Histo-MRI</acronym>
  <official_title>Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiparametric magnetic resonance imaging (mpMRI) is now widely used to risk stratify men&#xD;
      with a suspicion of prostate cancer and identify suspicious regions for biopsy. Advanced MRI&#xD;
      techniques have emerged which seek to improve this characterisation and could predict biopsy&#xD;
      results non-invasively before men undergo biopsy. Before these techniques are translated&#xD;
      clinically, robust histological and clinical validation is required.&#xD;
&#xD;
      This study aims to clinically validate advanced MRI techniques in a cohort of men suspected&#xD;
      with prostate cancer. Histological analysis of men undergoing biopsy, +/- prostatectomy will&#xD;
      be used for biological validation of VERDICT; Vascular and Extracellular Restricted Diffusion&#xD;
      for Cytometry in Tumours and Luminal Water imaging (LWI). In particular, prostatectomy&#xD;
      specimens will be processed using 3-D printed patient-specific moulds to allow for accurate&#xD;
      MRI and histology mapping.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy of VERDICT MRI</measure>
    <time_frame>2 years</time_frame>
    <description>Quantitative assessment of VERDICT MRI reduces false positives by 10% compared to standard MRI alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy of Luminal Water Imaging (LWI)</measure>
    <time_frame>2 years</time_frame>
    <description>Quantitative assessment of LWI reduces false positives by 10% compared to standard MRI alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportions of true positives with index tests is the same as mpMRI.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Machine learning algorithms can predict histology from MRI.</measure>
    <time_frame>3 years</time_frame>
    <description>Number of correct predictions of gleason grade in men who undergo biopsy or prostatectomy.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Neoplasm</condition>
  <arm_group>
    <arm_group_label>Men suspected of Prostate Cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>VERDICT MRI</intervention_name>
    <description>Advanced Diffusion Model</description>
    <arm_group_label>Men suspected of Prostate Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Luminal Index Imaging</intervention_name>
    <description>Advanced T2 mapping</description>
    <arm_group_label>Men suspected of Prostate Cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Prostatectomy and biopsy specimens&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of men presenting to our recruitment centre with suspicion of prostate cancer due to&#xD;
        raised prostate specific antigen level or suspicious clinical examination.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men aged 18-90 with a clinical suspicion of prostate cancer&#xD;
&#xD;
          -  No contraindication to MRI&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Men unable to have a MRI scan, or in whom artefact would reduce quality of MRI&#xD;
&#xD;
          -  Men unable to given informed consent&#xD;
&#xD;
          -  Previous treatment (prostatectomy, radiotherapy, brachytherapy) of prostate cancer&#xD;
&#xD;
          -  Ongoing hormonal treatment for prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participant eligibility is based on self-representation of gender identity. Men with clinical suspicion of prostate cancer.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shonit Punwani</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joey Clemente</last_name>
    <phone>07886178028</phone>
    <email>j.clemente@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joey Clemente</last_name>
      <phone>07886178028</phone>
      <email>j.clemente@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenobarbital</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

